Ind-Swift Laboratories Ltd. has multi locational manufacturing sites for producing APIs. The cGMP manufacturing facility at Punjab with 22 manufacturing blocks comprises of a Pilot Plant, dedicated blocks and multi-purpose blocks designed to comply with stringent USFDA and other regulatory standards of approval.
An API manufacturing facility in the state of Jammu & Kashmir complying with cGMP requirements is adding to the capacities of organization.
The company possesses one of the largest cumulative reactor capacities in North India. Complex reaction capabilities and stringent controls provide an ideal base for innovative and quality products.
Our capacity build up is based upon our focus on operational excellence and quality circles. The philosophy of our manufacturing excellence is to continuously improve on processes, eliminate inefficiencies and facilitate lean procedures. Our flagship manufacturing site at Derabassi is periodically inspected and audited by regulatory authorities like USFDA, KFDA, PMDA, ANVISA, EDQM among others. Continues operation through a well-established regulatory framework ensures that all our plants can consistently deliver products of global quality standards.
We have ensured world-class quality in design, equipment and operations in our both the manufacturing facilities. These manufacturing units are in North India.
The Derabassi manufacturing facility is regularly inspected by local and international health authorities, such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and many others.
The API Jammu, India facility is fully complying with cGMP requirements.
The Manufacturing sites having complex reaction capabilities and stringent controls which provide an ideal base for innovative and quality products.
ISLL facilities operate in full compliance with Current Good Manufacturing Practice (cGMP) regulations, which are an integral part of the comprehensive quality assurance system.
- Twenty two dedicated and multipurpose cGMP manufacturing plants.
- Pilot plant facility.
- Dedicated facility for Oncology Products with world class Isolators.
- Dedicated Oral Solid Dosage facility for largest product Clarithromycin Granules.
- Four Solvent Recovery Plant.
- Three Dedicated and multipurpose cGMP manufacturing plants.
Derabassi, India (API Production facility)
- Installed Reaction Capacity of 505 KL with 185 Stainless Steel reactors and 50 Glass lined reactors, facility is equipped with cryogenic reactor
- 200 MT production capacity every month for Intermediate and APIs
- 2000 KL solvent distillation capacity every month
- High Pressure hydrogenation facility up to 20 kg/cm2
- GMP pilot plant suitable for advance intermediate, Key starting Material and for API
- Purified water system to meet USP39 Quality
- ZERO discharge facility
Jammu, India (API Production Facility)
- Installed Reaction Capacity of 162 KL
- 30 MT API Production capacity every month
Facility is equipped with the storage capacity of 1200 KL liquid and 350 MT solid with controlled temperature storage.